240 related articles for article (PubMed ID: 17043358)
1. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
Gan B; Yoo Y; Guan JL
J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358
[TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway.
Crossland H; Kazi AA; Lang CH; Timmons JA; Pierre P; Wilkinson DJ; Smith K; Szewczyk NJ; Atherton PJ
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E183-93. PubMed ID: 23695213
[TBL] [Abstract][Full Text] [Related]
3. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control.
Gan B; Melkoumian ZK; Wu X; Guan KL; Guan JL
J Cell Biol; 2005 Aug; 170(3):379-89. PubMed ID: 16043512
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
6. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin.
Shumway SD; Li Y; Xiong Y
J Biol Chem; 2003 Jan; 278(4):2089-92. PubMed ID: 12468542
[TBL] [Abstract][Full Text] [Related]
11. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex.
Shah OJ; Hunter T
J Biol Chem; 2004 May; 279(20):20816-23. PubMed ID: 14993219
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
Li Y; Inoki K; Guan KL
Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
[TBL] [Abstract][Full Text] [Related]
13. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.
Copps KD; Hançer NJ; Qiu W; White MF
J Biol Chem; 2016 Apr; 291(16):8602-17. PubMed ID: 26846849
[TBL] [Abstract][Full Text] [Related]
14. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway.
Cao Y; Kamioka Y; Yokoi N; Kobayashi T; Hino O; Onodera M; Mochizuki N; Nakae J
J Biol Chem; 2006 Dec; 281(52):40242-51. PubMed ID: 17077083
[TBL] [Abstract][Full Text] [Related]
15. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
16. AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha.
Arvisais EW; Romanelli A; Hou X; Davis JS
J Biol Chem; 2006 Sep; 281(37):26904-13. PubMed ID: 16816403
[TBL] [Abstract][Full Text] [Related]
17. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
18. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
Ravitz MJ; Chen L; Lynch M; Schmidt EV
Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
[TBL] [Abstract][Full Text] [Related]
19. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
20. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
